Background

Co-founder & CEO of MolAIcule; extensive experience in AI-driven drug discovery and technology ventures.

Expertise

• AI platform strategy and development
• Translational partnerships & collaborations
• Biotech business development
• Cross-disciplinary leadership

Vision

Revolutionize drug discovery through agentic-AI molecular design and development.

Background

Co-founder with deep expertise in peptide chemistry and medicinal chemistry.

Expertise

• Peptide synthesis & modification
• Macrocycle design & optimization
• Peptidomimetic development
• Drug-like scaffold engineering
• SAR & property tuning

Focus

Innovative peptide-based therapeutics with enhanced stability, selectivity, and developability.

Background

Co-founder with extensive experience bridging basic biology and clinical translation.

Expertise

• Cancer target validation
• In vivo pharmacology & toxicology
• Translational strategy
• Preclinical development
• Regulatory pathways

Leadership

Advanced multiple therapeutics from discovery to clinical development.

Background

Scientific Advisor and Adjunct Professor at University of Michigan. Over 29 years of industrial experience in medicinal chemistry across oncology, antiviral, metabolic disease, CNS, anti-inflammatory, and dermatology therapeutic areas.

Expertise

• Medicinal chemistry & drug design
• Fragment-based drug discovery (FBDD)
• DNA-encoded library (DEL)
• Bioisosteres & SAR optimization
• ADME/Tox & pharmacokinetics
• Process chemistry & scale-up

Key Achievements

• Contributed to 2 drug candidates to Phase II
• Contributed to 5 drug candidates to Phase I
• Co-inventor of BMS-823778 (Phase II, 11β-HSD1 inhibitor for type II diabetes)
• Led multiple project teams at Pfizer, BMS, and Revolution Medicines
• Published 35+ peer-reviewed articles and 35+ books on medicinal chemistry

Professional Experience

• University of Michigan — Adjunct Professor, Medicinal Chemistry (2022–Present)
• ChemPartner — Vice President, Discovery Chemistry (2019–2021)
• Revolution Medicines — Principal Scientist, Medicinal Chemistry (2017–2019)
• University of San Francisco — Associate Professor and Graduate Director (2013–2017)
• Bristol-Myers Squibb — Senior Research Investigator II (2007–2013)
• Pfizer Global R&D — Senior Principal Scientist (2000–2007)
• Parke-Davis Pharmaceuticals — Senior Scientist/Scientist (1997–2000)

Background

Distinguished Professor, UC San Diego; former Director, Ludwig Institute for Cancer Research (San Diego) and Director of Strategic Alliances in CNS Cancers at Ludwig Cancer Research.

Honors & Societies

• Elected Member, U.S. National Academy of Sciences & National Academy of Medicine
• Foreign Member, German National Academy of Sciences Leopoldina & Chinese Academy of Engineering
• Fellow, AAAS & American Association for Cancer Research; Member, ASCO & ASCI
• Szent-Györgyi Prize for Progress in Cancer Research (NFCR)

Leadership

30+ years shaping cancer genetics and translational oncology; advisor to biopharma & academia on tumor biology, biomarkers, and therapeutic development.

Experience

• Chief Scientific Officer, Alebund Pharmaceuticals (2025– ) — portfolio strategy; end-to-end development & global regulatory
• Chief Medical Officer, Hasten (2024–2025); CSO/CMO at 3D Medicines (2021–2024)
• U.S. FDA/CDER (2002–2021) — Senior Medical Officer (prev. Medical Officer; Pharm/Tox Reviewer); IND/NDA/BLA leadership; cross-center cardio-renal safety & guidance

Honors

CDER Scientific Achievement Award; APS Excellence in Renal Research Award